Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600750's PB Ratio is ranked worse than 72.99% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.96
vs SHSE:600750: 3.66
During the past 12 months, China Resources Jiangzhong Pharmaceutical Co's average Book Value Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Resources Jiangzhong Pharmaceutical Co was 25.50% per year. The lowest was -1.10% per year. And the median was 8.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Resources Jiangzhong Pharmaceutical Co PB Ratio Related Terms
China Resources Jiangzhong Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co PB Ratio Chart
China Resources Jiangzhong Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Jiangzhong Pharmaceutical Co PB Ratio vs Drug Manufacturers Industry
China Resources Jiangzhong Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a PB Ratio of 3.66 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. This is 43% above median its historical median of 2.56. Over the past decade, China Resources Jiangzhong Pharmaceutical Co's PB Ratio has ranged from 1.64 to 4.56. According to the industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #673 out of 922 companies in the Drug Manufacturers industry, placing it in the top 73%.
Is China Resources Jiangzhong Pharmaceutical Co's PB Ratio too high?
China Resources Jiangzhong Pharmaceutical Co's current PB Ratio of 3.66 is 43% above median its 10-year median of 2.56. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 4.56. The Drug Manufacturers industry median PB Ratio is 1.96. China Resources Jiangzhong Pharmaceutical Co's value of 3.66 is 86.7% above this industry median. Based on the distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #673 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #673 out of 922 companies for PB Ratio. This places China Resources Jiangzhong Pharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 1.96. China Resources Jiangzhong Pharmaceutical Co's value of 3.66 is 86.7% above this benchmark. Historically, China Resources Jiangzhong Pharmaceutical Co's own PB Ratio has ranged from 1.64 to 4.56 over the past decade. While the company's 10-year median is 2.56 vs. the industry median of 1.96, China Resources Jiangzhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Jiangzhong Pharmaceutical Co's current PB Ratio of 3.66 is 86.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Jiangzhong Pharmaceutical Co's current PB Ratio is 3.66, which is 43% above median its own 10-year median of 2.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥20.87, compared to a current price of ¥24.86 — trading 19.1% above its estimated fair value. The current PB Ratio is 3.66, which is 43% above median its 10-year median of 2.56 and 86.7% above the Drug Manufacturers industry median of 1.96. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current PB Ratio is 3.66 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.86 is trading 19.1% above its estimated GF Value™ of ¥20.87.
GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600750:
PB Ratio: 3.66 (43% above median its 10-year median of 2.56)
GF Value™: ¥20.87 vs. price of ¥24.86 (19.1% above fair value)
Industry Position: 86.7% above the Drug Manufacturers median (#673 of 922)
No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
86GF Score
Get the complete analysis for SHSE:600750
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600750 has been successfully added to your 
